EDITOR—Although we agree with the conclusions of the survey reported by Noble et al of patients' views on receiving low molecular weight heparin in palliative care, we wish to sound some notes of caution.1 Reasons other than preciousness about patients' comfort lie behind a reluctance to give many patients in palliative care prophylactic treatment with low molecular weight heparin. In advanced cancer …
No takes yet. Share an insight, caveat, or question.
Pace et al. (2006) studied this question.